SpringWorks Therapeutics, Inc. (SWTX)
NASDAQ: SWTX · Real-Time Price · USD
34.43
-2.69 (-7.25%)
At close: Apr 10, 2025, 4:00 PM
34.71
+0.28 (0.83%)
After-hours: Apr 10, 2025, 7:13 PM EDT
SpringWorks Therapeutics Revenue
In the year 2024, SpringWorks Therapeutics had annual revenue of $191.59M with 3,417.33% growth. SpringWorks Therapeutics had revenue of $61.55M in the quarter ending December 31, 2024, with 1,029.96% growth.
Revenue (ttm)
$191.59M
Revenue Growth
+3,417.33%
P/S Ratio
13.32
Revenue / Employee
$520,622
Employees
368
Market Cap
2.58B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SWTX News
- 14 days ago - Biotech stocks have been hit hard. Why they're a great value now. - Market Watch
- 4 weeks ago - SpringWorks Therapeutics: Promising Launches, Expanding Pipeline, And M&A Buzz - Seeking Alpha
- 7 weeks ago - Top 3 Health Care Stocks You May Want To Dump In February - Benzinga
- 7 weeks ago - SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates - GlobeNewsWire
- 7 weeks ago - SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over - PRNewsWire
- 7 weeks ago - Onco360 Has Been Selected as a National Specialty Pharmacy Partner for GOMEKLI™ (mirdametinib), Manufactured By SpringWorks Therapeutics - GlobeNewsWire
- 2 months ago - UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN - GlobeNewsWire
- 2 months ago - SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN - GlobeNewsWire